BioNTech SE (BNTX) Tops Q3 EPS, Warns on COVID Revenue

BioNTech SE (NASDAQ: BNTX) reported Q3 EPS of EUR0.67, EUR0.05 better than the analyst estimate of EUR0.62. Revenue for the quarter came in at EUR895.3 million versus the consensus estimate of EUR837.61 million.

GUIDANCE:

Updated 2023 COVID-19 vaccine revenue guidance of around EUR4 billion, versus EUR5 billion prior.

For earnings history and earnings-related data on BioNTech SE (BNTX) click here.

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Jana Partners urges Cooper Companies to replace CEO and explore asset sales
• Can global equities keep rising? UBS sees these factors driving upside